Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival. - Wikidata - awgldk - TriplyDB

Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival.

Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival.

http://www.wikidata.org/entity/Q34633368

about

Current classification, treatment options, and new perspectives in the management of adipocytic sarcomas High-dose continuous-infusion ifosfamide in advanced well-differentiated/dedifferentiated liposarcoma Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma.Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas Epidemiology and therapies for metastatic sarcoma Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy.Retroperitoneal sarcomas: patterns of care in advanced stages, prognostic factors and focus on main histological subtypes: a multicenter analysis of the French Sarcoma Group.Aplidin in patients with advanced dedifferentiated liposarcomas: a French Sarcoma Group Single-Arm Phase II study Tumor-associated fibroblasts promote the proliferation and decrease the doxorubicin sensitivity of liposarcoma cells.Hypothesis: The Intratumoral Immune Response against a Cancer Progenitor Cell Impacts the Development of Well-Differentiated versus Dedifferentiated Disease in Liposarcoma Innovative approaches to establish and characterize primary cultures: an ex vivo 3D system and the zebrafish model.Comprehensive adipocytic and neurogenic tissue microarray analysis of NY-ESO-1 expression - a promising immunotherapy target in malignant peripheral nerve sheath tumor and liposarcoma.Differential expression of cysteine dioxygenase 1 in complex karyotype liposarcomas.Assessing the clinical value of microRNAs in formalin-fixed paraffin-embedded liposarcoma tissues: Overexpressed miR-155 is an indicator of poor prognosis.Anti‑proliferative activity of epigallocatechin‑3‑gallate and silibinin on soft tissue sarcoma cells.Novel systemic therapies in advanced liposarcoma: a review of recent clinical trial results Current management options for liposarcoma and challenges for the future.A newly characterized human well-differentiated liposarcoma cell line contains amplifications of the 12q12-21 and 10p11-14 regions.Contemporary Management of Retroperitoneal Soft Tissue Sarcomas.Activation of the Akt-mTOR and MAPK pathways in dedifferentiated liposarcomas.Pharmacological therapies for Liposarcoma.Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations.Analysis of the intratumoral adaptive immune response in well differentiated and dedifferentiated retroperitoneal liposarcoma.MDM2 antagonists synergize with PI3K/mTOR inhibition in well-differentiated/dedifferentiated liposarcomas Role of chemotherapy in dedifferentiated liposarcoma of the retroperitoneum: defining the benefit and challenges of the standard.Can Abdominal Computed Tomography Imaging Help Accurately Identify a Dedifferentiated Component in a Well-Differentiated Liposarcoma?Systemic Therapy in Metastatic or Unresectable Well-Differentiated/Dedifferentiated Liposarcoma.Systemic therapy in retroperitoneal sarcoma management.Multiply recurrent retroperitoneal liposarcoma.Surgery for Abdominal Well-Differentiated Liposarcoma.Curcumin and Viscum album Extract Decrease Proliferation and Cell Viability of Soft-Tissue Sarcoma Cells: An In Vitro Analysis of Eight Cell Lines Using Real-Time Monitoring and Colorimetric Assays.Targeted next generation sequencing of well-differentiated/dedifferentiated liposarcoma reveals novel gene amplifications and mutations.Refractory bleeding from a giant de-differentiated liposarcoma of the chest wall: An indication for neoadjuvant chemotherapy and palliative resection? - A case report

P2860

Q28076210-AF8C6D67-19F4-4A97-94F5-57BC63DCD2AF Q33420031-FC8A7C50-E1E3-4E34-BDA2-716CD1F072C2 Q33434141-8B4390F9-93D5-4266-A8B1-85D8AE8BAF0B Q33815063-0A97F3BC-9C3B-496D-A041-630F24C13422 Q34652142-F4CA2D02-2072-4C04-9181-3D53B28A2184 Q34736667-94726D0A-67FB-426A-B9D7-EE80F4DF8E1E Q35611855-0606932D-9471-48E1-BDF6-9414B002E80B Q35775249-DE49C8FD-5818-47A6-96F1-9F20DDEB45E7 Q36903707-ADD512F3-1597-49F0-BF57-881F03D1A3DE Q36989914-7964BA82-958B-4C33-81DF-AE5EAA8DA44C Q37644536-2F3996FE-1854-4D5A-BEA1-7F327BEC7E44 Q37687307-8497078A-1CE6-4E9C-A32F-17065CA3D493 Q37694523-81D51EBF-4C76-4239-BD13-624DB181568F Q37701702-6E9F6A28-CFA3-4816-B7EC-762CCF31DE09 Q37707691-EB352AEC-5782-4B48-B23B-D0D591FE5027 Q38161734-15A882EC-21AB-40EA-AAF8-82AAB46169C2 Q38176387-DE63762A-707B-4CED-8460-1ABF9D5FBD90 Q38432241-14B61F68-F82E-4C7D-B4A1-4BFCB015CAAD Q38532600-20D08729-2E27-46B9-8457-7D7C5A02D9DD Q38823442-795162E4-4B0E-43CC-994E-87B7A5DF0CFA Q38991731-7B7FB364-B816-4157-8285-BE6A9D3AADE0 Q41105379-20B6E1F1-59E1-4220-980A-CA14C5B1536F Q41370229-191C4FF9-14CD-44B4-90AE-F2FB5C5C3CF9 Q41553688-6FE1268A-6BA6-4CF3-85FE-8B6D09DB40A5 Q41717674-6D8CF9E9-581E-48CC-98C2-D0CA555343F0 Q42746834-6E03DCC1-361F-4D31-BBB6-B73BC3A563B0 Q47144710-ACC5A476-3525-4BB5-8D33-B765E5918B90 Q47384577-63604121-09F4-496B-8864-3894C63E40D9 Q48369179-E0B738ED-39EC-4552-B9C8-E141F4D55574 Q50041583-4C238C15-12A5-457D-803A-5C2759A86206 Q50976238-22261E6B-CA8C-4905-9976-D9D777C4659A Q55349624-BB9FD7FA-3544-4DB4-B493-E4481A8B87E6 Q58792969-C30E8222-41FF-4193-9668-F88EDFFEB9B4

P2860

Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival.

http://www.wikidata.org/entity/Q34633368

description

2011 nî lūn-bûn

@nan

2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

name

Advanced well-differentiated/d ...... of chemotherapy and survival.

@ast

Advanced well-differentiated/d ...... of chemotherapy and survival.

@en

Advanced well-differentiated/d ...... of chemotherapy and survival.

@nl

type

label

Advanced well-differentiated/d ...... of chemotherapy and survival.

@ast

Advanced well-differentiated/d ...... of chemotherapy and survival.

@en

Advanced well-differentiated/d ...... of chemotherapy and survival.

@nl

prefLabel

Advanced well-differentiated/d ...... of chemotherapy and survival.

@ast

Advanced well-differentiated/d ...... of chemotherapy and survival.

@en

Advanced well-differentiated/d ...... of chemotherapy and survival.

@nl

P1433

Q34633368-693414AC-8868-41B8-865B-35F20D0BA883

P1476

Q34633368-1C214D4B-5213-460B-981B-A89C383D6D38

P2093

Q34633368-3D57E303-0604-4F82-A5E6-1897CCB545C5

Q34633368-50B8C162-C174-408B-B790-3D28425BDF3F

Q34633368-62BDA820-56CF-4C7B-B66D-7151EFC35F6C

Q34633368-6B3A60FA-0055-46DB-AC9C-28BCC772FB0A

Q34633368-6B9589F2-8B26-4599-A42E-0FDE54AE6641

Q34633368-7561C09F-078B-4A38-860C-EA1626953293

Q34633368-9889F88D-A3B5-49AC-815E-D2E60FBBB243

Q34633368-B174A13A-98EA-4C80-A1D9-3BAE7E969390

Q34633368-B24B48A9-E034-457D-ABCD-5EAC8BA415F5

Q34633368-B4DA0A39-44EB-4332-AE5F-DA3FEB81CCAB

P2860

Q34633368-0228FE21-62DA-446F-9317-44EFE7DE7CD9

Q34633368-0B85457D-1B1C-43BA-8433-C4BF671ED369

Q34633368-151C1013-93F3-47CB-B8BE-13DFF6A17B87

Q34633368-2D8C6791-BAE7-4B91-BA08-D483E62721EF

Q34633368-3484BF24-E540-4228-89F6-0E068078C5C6

Q34633368-397A852D-4374-4984-B664-AA7A19530E62

Q34633368-3C37A49D-50B5-4012-B3AE-8D7C438735AE

Q34633368-3E856BDA-3447-41A8-A99C-2F0EFD0AAF3E

Q34633368-55F2B846-4821-4103-B1BD-B96A7D543BC4

Q34633368-5BBA99B5-9748-4324-8AE1-1E802E73C514

P304

Q34633368-2AA073C4-1AAA-48CB-A825-4146CBF9B297

P31

Q34633368-2CED5600-0185-4306-A0A4-9A30DB2717E3

P356

Q34633368-A87E869A-A84B-42EA-BDCE-EA8F9549EDAC

P433

Q34633368-916008C4-7D77-4CBA-BD11-F0B97F8B267C

P478

Q34633368-47EF6076-43E6-4382-926D-30098511F438

P50

Q34633368-2FE6DA6B-5F9D-4145-ABEC-20CD37BBED58

Q34633368-B998823B-68BA-4A0E-8F61-2BC90DF9888D

Q34633368-BEF578DF-3200-465F-9B11-C8C49DE636F9

P577

Q34633368-7325E64E-3A70-4505-96A6-6725661A6458

P698

Q34633368-228E3AA3-DC53-4652-AE8B-5F3483527C83

P921

Q34633368-279DF525-4F35-4E79-B81B-E3EBF6CD41E8

P356

P1433

Annals of Oncology

P1476

Advanced well-differentiated/d ...... of chemotherapy and survival.

@en

P2093

A Cioffi

http://www.w3.org/2001/XMLSchema#string

A Italiano

http://www.w3.org/2001/XMLSchema#string

A Patrikidou

http://www.w3.org/2001/XMLSchema#string

B Bui

http://www.w3.org/2001/XMLSchema#string

B Lortal

http://www.w3.org/2001/XMLSchema#string

C R Antonescu

http://www.w3.org/2001/XMLSchema#string

E Bompas

http://www.w3.org/2001/XMLSchema#string

F Duffaud

http://www.w3.org/2001/XMLSchema#string

G K Schwartz

http://www.w3.org/2001/XMLSchema#string

J-M Coindre

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma

MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data.

Involvement of c-jun in human liposarcoma growth: supporting data from clinical immunohistochemistry and DNAzyme efficacy.

Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.

Added Value of Molecular Biological Analysis in Diagnosis and Clinical Management of Liposarcoma: A 30-Year Single-Institution Experience.

Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and

Differential sensitivity of liposarcoma subtypes to chemotherapy.

Can MDM2 and CDK4 make the diagnosis of well differentiated/dedifferentiated liposarcoma? An immunohistochemical study on 129 soft tissue tumours.

An experimental model for the study of well-differentiated and dedifferentiated liposarcoma; deregulation of targetable tyrosine kinase receptors.

P304

1601-1607

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDR485

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-10-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22039081

http://www.w3.org/2001/XMLSchema#string

P921